Pegaspargase for treating acute lymphoblastic leukaemia

  • Technology appraisal guidance
  • TA408
  • Published: 
Download guidance (PDF)

3 Evidence

The appraisal committee (section 6) considered evidence submitted by Baxalta (now part of Shire Pharmaceuticals) and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence.